Food

 

Newly released market study: Global Coronary Artery Disease Therapeutics Market 2017-2021



22.11.2017 14:54:20 - Recently published research from TechNavio, "Global Coronary Artery Disease Therapeutics Market 2017-2021", is now available at Fast Market Research

(live-PR.com) - YEAR-END RESEARCH SALE!
- This report might qualify for up to a 30% DISCOUNT if purchased before the end of 2017
- More details at www.fastmr.com/prod/1309413_global_coronary_arte ..

Coronary artery disease (CAD) is the most common type of heart disease and is one of the leading causes of death globally. It can lead to complications including myocardial infarction, stable angina, unstable angina, and

 

sudden cardiac death. CAD is the narrowing of the coronary arteries that prevents the supply of an adequate amount of blood supply to the heart. It happens when a coronary artery gets hardened or narrowed due to various reasons such as the build-up of cholesterol or other materials known as plaque on the inner wall of the artery. This build-up is known as atherosclerosis. With passing time, a lesser amount of blood flows through the arteries. As a result heart muscle fails to get the required amount of blood or oxygen.

Technavio's analysts forecast the global coronary artery disease therapeutics market to grow at a CAGR of 5.17% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global coronary artery disease therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

* Americas
* APAC
* EMEA

Technavio's report, Global Coronary Artery Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

* AstraZeneca
* Gilead
* Novartis
* Pfizer

Other prominent vendors

* Bayer,
* Bristol-Myers Squibb,
* GlaxoSmithKline,
* Merck,
* Mylan,
* Teva Pharmaceutical Industries

Market driver

* Growing geriatric population
* For a full, detailed list, view our report

Market challenge

* Highly genericized market
* For a full, detailed list, view our report

Market trend

* Growing strategic alliances
* For a full, detailed list, view our report

Key questions answered in this report

* What will the market size be in 2021 and what will the growth rate be?
* What are the key market trends?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: AstraZeneca, Gilead, Novartis, Pfizer, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Mylan, Teva Pharmaceutical Industries

Browse our complete collection of Healthcare research reports at www.fastmr.com/catalog/browse.aspx?category=15&a ..

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)


Author:
Bill Thompson
e-mail
Web: http://www.fastmr.com
Phone: 1.413.485.7001


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Live-PR.com Contact Us